ROBERT ROBBINS, M.D.
Radiology at Pasteur Dr, Palo Alto, CA
License number
California A46093
Category
Radiology
Type
Thoracic Surgery (Cardiothoracic Vascular Surgery)
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 498-5710
Organization information
See more information about ROBERT ROBBINS at bizstanding.comRobert Robbins MD
300 Pasteur Dr, Stanford, CA 94305
Industry:
Thoracic Surgery, Surgeons
Site:
Phone:
(650) 725-6954 (Phone)
Description:
There are 34 doctors at this site. Surgery is not performed at this site.
Robert Clayton Robbins
Professional information
Robert C Robbins, Stanford CA
Specialties:
Surgeon
Address:
300 Pasteur Dr, Stanford, CA 94305
Board certifications:
American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery (Thoracic Surgery)
Robert Clayton Robbins, Stanford CA
Specialties:
Thoracic Surgery, Cardiothoracic Vascular Surgery, Surgery, Adult Medicine
Work:
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305 Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304
300 Pasteur Dr, Stanford, CA 94305 Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304
Education:
University of Mississippi(1983)
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
6605115, Aug 12, 2003
Filed:
Jun 5, 2000
Appl. No.:
09/587647
Inventors:
John P. Cooke - Palo Alto CA
Garrison C. Fathman - Portola Valley CA
Jonathan B. Rothbard - Woodside CA
Shiro Uemura - Nara, JP
Robert C. Robbins - Stanford CA
Murray H. Kown - Menlo Park CA
Garrison C. Fathman - Portola Valley CA
Jonathan B. Rothbard - Woodside CA
Shiro Uemura - Nara, JP
Robert C. Robbins - Stanford CA
Murray H. Kown - Menlo Park CA
Assignee:
Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61F 206
US Classification:
623 148, 623 142
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.
Methods And Compositions For Reducing Injury To A Transplanted Organ
US Patent:
2006014, Jul 6, 2006
Filed:
Nov 10, 2005
Appl. No.:
11/271285
Inventors:
Masashi Tanaka - Saitama-City, JP
Robert Robbins - Stanford CA, US
Robert Robbins - Stanford CA, US
International Classification:
A01N 1/02
US Classification:
514012000, 435001100
Abstract:
Methods for reducing injury to a transplanted mammalian organ or tissue, including inhibiting the development of graft blood vessel disease, are provided. In one form, a method includes administering compositions that include one or more PKC regulators to an organ or tissue donor and an organ or tissue recipient. Methods for decreasing or otherwise modulating an inflammatory response in a mammal are also provided. In one form, a method includes administering one or more regulators of protein kinase C to a patient in need thereof prior to, during or after an event giving rise to an inflammatory response. Methods for inhibiting, or otherwise modulating, a pro-apoptotic event are also provided. In one form, a method includes administering a therapeutically effective amount of an agonist of ε protein kinase C, and optionally an inhibitor of δ protein kinase C.
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
2006016, Jul 27, 2006
Filed:
Dec 20, 2005
Appl. No.:
11/316519
Inventors:
John Cooke - Palo Alto CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
International Classification:
A61F 2/04
US Classification:
604008000, 514002000
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
2006015, Jul 20, 2006
Filed:
Dec 20, 2005
Appl. No.:
11/316304
Inventors:
John Cooke - Palo Alto CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61F 2/02
US Classification:
424423000, 514002000
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.
Transmural Ablation Device
US Patent:
2013013, May 23, 2013
Filed:
Nov 30, 2010
Appl. No.:
13/512493
Inventors:
Paul J. Wang - Saratoga CA, US
Amin Al-Ahmad - Cupertino CA, US
William Francis Johnston - Sunnyvale CA, US
Kai Ihnken - Arlington VA, US
Kaartiga Sivanesan - Winter Springs FL, US
Morgan Clyburn - Menlo Park CA, US
Kathleen Lee Kang - Sunnyvale CA, US
Lauren Shui Sum Chan - San Francisco CA, US
Robert C. Robbins - Stanford CA, US
Friedrich B. Prinz - Woodside CA, US
Amin Al-Ahmad - Cupertino CA, US
William Francis Johnston - Sunnyvale CA, US
Kai Ihnken - Arlington VA, US
Kaartiga Sivanesan - Winter Springs FL, US
Morgan Clyburn - Menlo Park CA, US
Kathleen Lee Kang - Sunnyvale CA, US
Lauren Shui Sum Chan - San Francisco CA, US
Robert C. Robbins - Stanford CA, US
Friedrich B. Prinz - Woodside CA, US
International Classification:
A61B 18/14
US Classification:
606 41
Abstract:
A transmural ablation device is provided to achieve endocardial and epicardial ablation at the same site but directed from the inner and outer surfaces of the heart to create a transmural lesion. By ablating from both sides of the heart tissue, it is possible to increase the depth of the lesion created and to increase the likelihood of a transmural lesion. Embodiments pertain to techniques to align the endocardial and epicardial ablation elements and techniques to position and move the endocardial and epicardial ablation elements along a predefined linear, curvilinear, or circular path. The ability to bring the epicardial and endocardial elements more closely or firmly with the underlying tissue is important in creating optimal lesions. Magnetic force attracts the epicardial and endocardial elements.
Cardiomyocytes From Induced Pluripotent Stem Cells From Patients And Methods Of Use Thereof
US Patent:
2013002, Jan 31, 2013
Filed:
Jul 20, 2012
Appl. No.:
13/554946
Inventors:
Ning Sun - Stanford CA, US
Michael T. Longaker - Stanford CA, US
Robert C. Robbins - Stanford CA, US
Joseph Wu - Stanford CA, US
Feng Lan - Menlo Park CA, US
Andrew Stephen Lee - Palo Alto CA, US
Paul W. Burridge - Stanford CA, US
Michael T. Longaker - Stanford CA, US
Robert C. Robbins - Stanford CA, US
Joseph Wu - Stanford CA, US
Feng Lan - Menlo Park CA, US
Andrew Stephen Lee - Palo Alto CA, US
Paul W. Burridge - Stanford CA, US
International Classification:
C12Q 1/02, G01N 27/49, C40B 30/06, C12N 5/077, C40B 30/04, C40B 40/02, G01N 21/64, C12Q 1/68
US Classification:
506 9, 435 29, 435 612, 435366, 435 71, 435 611, 506 14, 506 10
Abstract:
Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
2004007, Apr 22, 2004
Filed:
May 20, 2003
Appl. No.:
10/442671
Inventors:
John Cooke - Palo Alto CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Nara, JP
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Nara, JP
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
International Classification:
A61F002/06
US Classification:
128/898000, 623/916000
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
2010011, May 6, 2010
Filed:
Sep 8, 2009
Appl. No.:
12/584609
Inventors:
John P. Cooke - Palo Alto CA, US
Garrison C. Fathman - Portola Valley CA, US
Jonathan B. Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert C. Robbins - Stanford CA, US
Murray H. Kown - Menlo Park CA, US
Garrison C. Fathman - Portola Valley CA, US
Jonathan B. Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert C. Robbins - Stanford CA, US
Murray H. Kown - Menlo Park CA, US
Assignee:
Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 38/16, A01N 1/02, A61K 38/08, A61K 38/10, A61P 9/00
US Classification:
514 12, 435 11, 514 16, 514 15, 514 17, 514 14, 514 13
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.